Clinical Trials Directory

Trials / Unknown

UnknownNCT05674565

Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries

The Neuroprotective Impact of Magnesium Sulphate Therapy for Preterm Deliveries. Loading Dose Alone Strategy Versus Loading Plus Maintenance Dose Strategy.

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
336 (estimated)
Sponsor
Zagazig University · Other Government
Sex
All
Age
24 Weeks – 34 Weeks
Healthy volunteers
Not accepted

Summary

A Cochrane systematic review has confirmed that fetal exposure to magnesium sulphate given before preterm birth has a neuroprotective role. This review also showed a significant reduction in the rate of gross motor dysfunction in early childhood. Early Preterm birth (\< 34+0 weeks) and very low birthweight (\< 1,500 g) are the principal risk factors for cerebral palsy. Multiple pregnancy accounts for over 10% of preterm births and has a higher incidence of cerebral palsy than singleton pregnancy (twins have 7 times and triplets 47 times the risk of cerebral palsy compared with singletons).

Detailed description

Many of these patients come or get diagnosed as eminent preterm delivery very soon before the real delivery happens and are not able to complete the recommended therapy of loading and maintenance strategy for at least complete 4 hours before delivery. Till now, there is a gap and lack of knowledge regarding the value of loading dose only as sufficient and effective strategy for neuroprotection compared to full therapy, which needs more health costs, longer monitoring and carries more risk for the patients.

Conditions

Interventions

TypeNameDescription
DRUGMagnesium sulfate loading with maintenance dose4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
DRUGMagnesium sulfate loading dose only4 gm MgSo4 loading over 20 minutes within one hour before delivery

Timeline

Start date
2023-01-20
Primary completion
2024-06-30
Completion
2024-07-15
First posted
2023-01-06
Last updated
2023-07-14

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05674565. Inclusion in this directory is not an endorsement.